Gov. Evers Highlights Risks of Federal Hemp Regulations in Wisconsin
Federal hemp regulations allowing delta-9 THC products to remain largely unregulated create patient safety concerns in Wisconsin. Clinicians face challenges due to unknown potency and contaminants in hemp products. Understanding federal hemp regulations…
Study Reveals Risks of Infrequent Cannabis Use in Adolescents
Infrequent adolescent cannabis use risks include measurable declines in academic performance and mental health outcomes. This study challenges assumptions about safe cannabis use thresholds in youth. Clinicians should counsel families that even…
Epic Handshake
Further Reading Cannabis NewsRecreational drugs triple the risk of stroke in young people, study finds | The Independent Evidence WatchDaily Digest 2026-03-08 CED Clinic BlogCannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years
Is This a Pigeon
# “Is This a Pigeon” Me, squinting at lab results: “Is this a clinically significant cannabinoid ratio, or just my patient’s interpretation of the budtender’s recommendation?” Further Reading Cannabis NewsRecreational…
Buff Doge vs Cheems
Buff Doge: “Peer-reviewed endocannabinoid research” vs. Cheems: “My cousin said it cured his thing” The evidence base has entered the chat, and it’s aggressively ripped. Further Reading Cannabis NewsRecreational drugs triple…
Review of Cannabinoids Safety and Efficacy in Pediatric Care
This review focuses on cannabinoids pediatric safety efficacy in clinical use, highlighting condition-specific evidence. Research supports cautious use in epilepsy and pain management among children. Clinicians should consider evolving data to guide…
Endocannabinoid System & Cannabis for Chronic Back Pain Trial
This phase 3 full-spectrum cannabis extract trial evaluated VER-01 for chronic low back pain in 820 adults. The study demonstrated significant pain reduction and good tolerability. These results support the potential of cannabis extract as an alternative…
Cannabinoid Efficacy in Chronic Pain: Updated Clinical Evidence
Clinical trials demonstrate cannabinoid efficacy chronic pain with modest reductions compared to placebo. The THC-to-CBD ratio and administration method influence outcomes. Patients and clinicians should consider these factors carefully.
Why Cannabis Rescheduling Alone Won’t Stabilize the Industry
The cannabis rescheduling impact could remove federal barriers to clinical research, enabling better prescribing decisions. However, without regulatory clarity, product consistency remains a challenge. Cannabis rescheduling impact alone won't stabilize…
Avecho Biotechnology Hits Milestone in Phase 3 Insomnia Trial
Avecho Biotechnology has reached a crucial milestone in its phase 3 insomnia trial cannabidiol study. This large-scale trial aims to provide robust efficacy and safety data for CBD as a treatment option. Clinicians should monitor this trial as it may…
